Trial Profile
Study of visual and anatomical outcomes of second year aflibercept in good visual acuity baseline of wet age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Sep 2017
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 13 Sep 2017 New trial record
- 26 Aug 2017 Status change from active no longer recruiting to completed.